Journal
RHEUMATOLOGY
Volume 53, Issue 7, Pages 1219-1228Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/ket481
Keywords
systemic lupus erythematosus; neuropsychiatric systemic lupus erythematosus; disease activity; GABA(B) receptor; autoantibody
Categories
Funding
- National Center for Global Health and Medicine [22A-104]
- Ministry of Health, Labor, and Welfare of Japan
Ask authors/readers for more resources
Methods. ELISA was performed with recombinant proteins of GABAR(B1b) and GABAR(B2) on serum samples from patients with SLE (n = 88), scleroderma (n = 20), myositis (n = 20) or vasculitis (n = 20) as well as healthy subjects (n = 20). Cerebrospinal fluid (CSF) from 23 patients with SLE was also examined. Results. Autoantibodies to GABAR(B)s were exclusive to patients with SLE (P < 0.001) and positively associated with SLEDAI (anti-GABAR(B1b), P = 0.001; anti-GABAR(B2), P < 0.001). Of note, autoantibodies were positively linked with NPSLE (anti-GABAR(B1b), P = 0.02; anti-GABAR(B2), P = 0.03). Moreover, anti-GABAR(B)s was detected in 61.5% of CSF samples from patients with active NPSLE, a frequency that was significantly higher than that for patients with non-SLE syndromes. Conclusion. Anti-GABAR(B) antibodies could represent novel candidate markers for disease activity and NPSLE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available